# EDGAR Filing Document

**Accession Number:** 0001929281
**File Stem:** 0001477932-23-001113
**Filing Date:** 2023-2
**Character Count:** 11940
**Document Hash:** e70263792b4be514fc38b3bcd0a309db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001113.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001477932-23-001113

**CONFORMED SUBMISSION TYPE**: 1-A POS

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioLIfe Sciences Inc
- **CENTRAL INDEX KEY:** 0001929281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 542013455
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** 1-A POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-11898
- **FILM NUMBER:** 23641625

**BUSINESS ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052
- **BUSINESS PHONE:** 647-470-2278

**MAIL ADDRESS:**
- **STREET 1:** 2831 SAINT ROSE PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052

## Part

**Post-Qualification Amendment No. 3** 

**File No. 024-11898**

 **EXPLANATORY NOTE** 

The sole purpose of this Post-Qualification Amendment No. 3 is to amend the exhibit index and to submit Exhibit 12.1, to correct certain scrivener's errors that were included in Exhibit 12.1 to Post-Qualification Amendment No. 2. Accordingly, this Post-Qualification Amendment No. 3 consists only of Part I, this Explanatory Note, Part III of the Offering Statement, the Signature Page to the Offering Statement, the exhibit index and the filed exhibit. No changes are being made to the Offering Circular and, therefore, the Offering Circular has been omitted from this filing.

**PART III - EXHIBITS**

**Index to Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| [2.1+](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex21.htm) | [Articles of Incorporation (Nevada)](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex21.htm) |
| [2.2+](http://www.sec.gov/Archives/edgar/data/1929281/000147793222009522/blfe_ex22.htm) | [Articles of Conversion (Nevada)](http://www.sec.gov/Archives/edgar/data/1929281/000147793222009522/blfe_ex22.htm) |
| [2.3+](http://www.sec.gov/Archives/edgar/data/1929281/000147793222009522/blfe_ex23.htm) | [Articles of Incorporation (Florida)](http://www.sec.gov/Archives/edgar/data/1929281/000147793222009522/blfe_ex23.htm) |
| [4.1+](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex41.htm) | [Form of Regulation A Subscription Agreement](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex41.htm) |
| [6.1+](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex61.htm) | [Purchase agreement with Health Box, LLC](http://www.sec.gov/Archives/edgar/data/1929281/000147793222003957/blfe_ex61.htm) |
| [11.2](blfe_ex121.htm) | [Consent of Newlan Law Firm, PLLC (included in Exhibit 12.1)](blfe_ex121.htm) |
| [12.1\*](blfe_ex121.htm) | [Opinion of Newlan Law Firm, PLLC as to legality of the offering](blfe_ex121.htm) |

---

_______________

\* Filed herewith.

+ Filed previously

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Henderson, Nevada, on February 17, 2023.

---

| | |
|:---|:---|
| **BIOLIFE SCIENCES, INC.**  | **BIOLIFE SCIENCES, INC.**  |
| By: | */s/ Justin De Four* |
|  | Justin De Four |
|  | Chairman, CEO and Director  |

---

This Offering Statement has been signed by the following person in the capacity and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Brian Morales* | Director | February 17, 2023  |
| */s/ Nika Jaksic* | Director | February 17, 2023  |
| */s/ Justin De Four* | Chairman, CEO and Director | February 17, 2023  |

---

## Ex1A-12

**EXHIBIT 12.1**

**NEWLAN LAW FIRM, PLLC**

**2201 Long Prairie Road – Suite 107-762**

**Flower Mound, Texas 75022**

**940-367-6154**

February 17, 2023

BioLife Sciences, Inc.

2831 St. Rose Parkway

#200

Henderson, Nevada 89052

Re: <u>Offering Statement on Form 1-A</u>

Gentlemen:

We have been requested by BioLife Sciences, Inc., a Florida corporation (the "Company"), to furnish you with our opinion as to the matters hereinafter set forth in connection with its offering statement on Form 1-A, including Post-Qualification Amendment No. 2 thereto (collectively, the "Offering Statement"), relating to the qualification of shares of the Company's $.001 par value common stock (the "Common Stock") under Regulation A promulgated under the Securities Act of 1933, as amended. Specifically, this opinion relates to 6,400,000,000 shares of the Company's Common Stock (the "Shares") to be offered by the Company.

In connection with this opinion, we have examined the Offering Statement, the Company's Articles of Incorporation and Bylaws (each as amended to date), copies of the records of corporate proceedings of the Company and such other documents as we have deemed necessary to enable us to render the opinion hereinafter expressed.

For purposes of this opinion, we have assumed the authenticity of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as copies and the authenticity of the originals of all documents submitted to us as copies. We have also assumed the legal capacity of all natural persons, the genuineness of the signatures of persons signing all documents in connection with which this opinion is rendered, the authority of such persons signing on behalf of the parties thereto other than the Company and the due authorization, execution and delivery of all documents by the parties thereto other than the Company. We have not independently established or verified any facts relevant to the opinions expressed herein, but have relied upon statements and representations of officers and other representatives of the Company and others.

Based upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set forth below, we are of the opinion that the 6,400,000,000 Shares being offered by the Company will, when issued in accordance with the terms set forth in the Offering Statement, be legally issued, fully paid and non-assessable shares of Common Stock of the Company.

Our opinions expressed above are subject to the qualification that we express no opinion as to the applicability of, compliance with, or effect of any laws except the Florida Statutes (including the statutory provisions and reported judicial decisions interpreting the foregoing).

We hereby consent to the use of this opinion as an exhibit to the Offering Statement and to the reference to our name under the caption "Legal Matters" in the Offering Statement and in the offering circular included in the Offering Statement. We confirm that, as of the date hereof, we own no shares of the Company's common stock, nor any other securities of the Company.

---

| |
|:---|
| Sincerely, |
| */s/ Newlan Law Firm, PLLC* |
| NEWLAN LAW FIRM, PLLC |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** BIOLIFE SCIENCES INC.

**Jurisdiction of Incorporation/Organization:** FL

**Year of Incorporation:** 2000

**CIK:** 0001929281

**I.R.S. Employer Identification Number:** 54-2013455

**Primary Standard Industrial Classification Code:** 2834

**Total number of full-time employees:** 1

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 2831 St. Rose Parkway #200, —, Henderson, NV 89052

**Company Phone:** 647-470-2278

**Person to contact:** Eric Newlan

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount      |
|:---|:---|
| Cash and Cash Equivalents                | $265623.00  |
| Investment Securities                    | $0.00       |
| Accounts and Notes Receivable            | $0.00       |
| Property, Plant and Equipment (PP&E)     | $980.00     |
| Total Assets                             | $1610441.00 |
| Accounts Payable and Accrued Liabilities | $758503.00  |
| Long-Term Debt                           | $0.00       |
| Total Liabilities                        | $1237864.00 |
| Total Stockholders' Equity               | $372577.00  |
| Total Liabilities and Equity             | $1610441.00 |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount      |
|:---|:---|
| Total Revenues                            | $0.00       |
| Costs and Expenses Applicable to Revenues | $0.00       |
| Depreciation and Amortization             | $0.00       |
| Net Income                                | $-774319.00 |
| Earnings Per Share - Basic                | -0.01       |
| Earnings Per Share - Diluted              | -0.01       |

**Auditor Information**

| Metric          | Amount   |
|:---|:---|
| Name of Auditor |  |

### Outstanding Securities

| Class   |   Outstanding | CUSIP     | Publicly Traded   |
|:---|---:|:---|:---|
| Common  |     771831732 | 76219W106 | OTC               |
|  |             0 |  |  |
|  |             0 |  |  |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier1

**Financial Statement Status:** Unaudited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** No

**Was or is the offering to commence within two days after qualification?** Yes

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 6400000000   |
| Number of securities outstanding                                | 771831732    |
| Price per security                                              | $0.00        |
| Issuer's aggregate offering price                               | $8320000.00  |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $5550157.00  |
| Total aggregate offering price                                  | $13870157.00 |

**Anticipated Fees**

| Service Provider   | Name                  | Fees      |
|:---|:---|:---|
| Auditor            |  | $0.00     |
| Legal              | Newlan Law Firm, PLLC | $15000.00 |
| Promoters          |  | $0.00     |

**Estimated Net Proceeds to the Issuer:** $13850157.00

### Item 5. Jurisdictions in Which Securities are to be Offered

- All States and Territories

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** BIOLIFE SCIENCES, INC.

**Title of Securities Issued:** Common Stock

**Total Amount of Securities Issued:** 297653148

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** $5,550,157; Board of Directors determination, terms of contract

**Basis for aggregate consideration:** —

**Securities Act Exemption:** Regulation A